GMA News
FDA chief: Carrimycin not part of solidarity trial of drugs vs. COVID-19, not registered in Philippines
The Food and Drug Administration (FDA) clarified that Carrimycin, a Chinese drug reportedly used by AFP Chief of Staff General Felimon Santos Jr. for his COVID-19 recovery, is not part of the Philippines' official clinical trials.
FDA chief Rolando Enrique Domingo stated that Carrimycin is an investigational drug used in China and has not been registered or sought permit for importation in the Philippines.
Domingo confirmed that the four drugs currently undergoing the Solidarity Trial in the country are Remdesivir, Chloroquine or Hydroxychloroquine, Lopinavir with Ritonavir, and Lopinavir with Ritonavir plus Interferon beta-1a.
He cautioned the public against purchasing drugs under trial, emphasizing that they are not preventive or prophylactic medications for COVID-19 but are being tested on patients who already have the disease to help manage their condition.
Separately, Domingo mentioned that Prodex-B, also considered for COVID-19 treatment, is currently under initial evaluation by the Department of Science and Technology (DOST).
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
